Rocket Pharmaceuticals, Inc. (RCKT)
$2.48-3.12%Close
SELLCRISIS · day 14
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $271M
- Beta
- 0.50
- P/E (TTM)
- -15.50
- Short % float
- 17.31%
- Days to cover
- 6.9
- SI change
- +1.4%
- 1W
- -4.98%
- 1M
- -25.97%
- vs SPY 1W
- -5.40%
- vs SPY 1M
- -28.03%
Industry peers
FMP comparable companies · ranked by market cap
- LBRXSELLLB Pharmaceuticals Inc Common Stock$1.1BCRISISQ 78$37.22-3.47%
- DSGNSELLDesign Therapeutics, Inc.$728MCRISISQ -13$11.65-6.35%
- AURASELLAura Biosciences, Inc.$676MRECOVERYQ -6$6.54+0.00%
- SLDBSELLSolid Biosciences Inc.$676MCRISISQ -13$6.87-2.33%
- ANNXSELLAnnexon, Inc.$659MRECOVERYQ -9$4.02-1.49%
- IMABI-Mab$542M$2.88
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on RCKT?
- LOPJLB’s latest quantitative signal on Rocket Pharmaceuticals, Inc. (RCKT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is RCKT in?
- Rocket Pharmaceuticals, Inc. (RCKT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Rocket Pharmaceuticals, Inc. (RCKT) do?
- Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, char…